Sole Source Notice for DiaSorin, INC Liaison XS and Liaison MDX Instruments

The State of Oregon has issued a sole source procurement notice for DiaSorin, Inc. clinical laboratory instruments and related services, posted on May 5, 2026, with a response deadline of May 13, 2026. This procurement encompasses the acquisition of DiaSorin Liaison XS and Liaison MDX automated immunoassay analyzers, along with associated reagents, quality control materials, maintenance services, technical support, and personnel training. Specifically, the state is procuring the LIAISON XL Analyzer (part number I0050) and LIAISON XS Analyzer (part number I0090), the LIAISON QuantiFERON Software (part number Q0001), and related diagnostic reagents including the LIAISON QuantiFERON TB Gold Plus Kit (200 tests) and associated controls. The procurement is designed to support Oregon's clinical laboratory testing requirements for high-volume immunoassay analysis capabilities and addresses the state's healthcare and laboratory operations needs. The sole source justification establishes that DiaSorin is the exclusive manufacturer and service provider of these specified systems, and no competitive alternatives exist that can meet the technical and operational requirements without significant system overhauls and operational disruptions. Pricing for equipment, reagent supplies, and service agreements will be based on DiaSorin's established fee schedules, with technical inquiries directed to Jay McConnell at 651-351-5698.

As a sole source procurement, this opportunity eliminates set-aside requirements and competitive bidding procedures, restricting the award exclusively to DiaSorin, Inc., the designated sole supplier. DiaSorin's authorized distributor for specified reagents is identified as QIAGEN Sciences, LLC. The procurement justification emphasizes that the integrated nature of DiaSorin's systems within Oregon's existing clinical laboratory infrastructure, combined with technical compatibility requirements and established laboratory workflows, necessitates the sole source determination. No alternative suppliers are identified as capable of meeting the state's specific technical, operational, and integration requirements. Funding for both the acquisition and ongoing operations will be sourced through Oregon's healthcare and laboratory operations budget allocations. The contract structure is designed to align with the state's budget cycles and operational needs for sustained clinical laboratory operations, though specific contract term, renewal options, and award values are not detailed in the posted procurement notice.